cyclophosphamide – Medxy AI

Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper

By MedXY 10/23/2025

Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glucocorticoid toxicity.

Nephrology news Rheumatology

Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS

By MedXY 10/23/2025

A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY 09/16/2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.

Clinical Updates Hematology-Oncology news Specialties

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

By MedXY 08/01/2025

Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.